Result of stereotactic radiotherapy of oligometastasis non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2017.10.007
- VernacularTitle:43例寡转移NSCLC立体定向放疗结果分析
- Author:
Xiaolong HU
1
;
Hongqi LI
;
Xiangsheng XU
;
Hefei LIU
;
Weizhang WU
;
Tingyi XIA
;
Yingjie WANG
Author Information
1. 北京老年医院肿瘤放疗科
- Keywords:
Lung neoplasms,oligometastasis;
Carcinoma,non-small cell lung/stereotactic radiotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2017;26(10):1141-1146
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the curative effect and adverse reaction of applying stereotactic radiotherapy to primary lesion inside chest cavity of patients with oligometastasis non-small cell lung cancer and rendering radical radiotherapy to all metastases. Methods 43 patients with≤5 metastases of non-small cell lung cancer received initial treatment during 2009-2015 in our department were analyzed;the stereotactic radiotherapy was adopted to implement radical radiotherapy on primary lesion and all metastases. The average and neutral position BED10 respectively were 101416 Gy and 102700 Gy,the number of neutral position chemotherapy period was 4. Kaplan-Meier method, survival analysis, Cox model, multi factor Prognosis analysis were used. Results By the end of January 10,2017 in 36 months' neutral position follow-up visit, the total effective rate of lesion treatment of 86%;the survival rates after 1,2 and 3 years respectively were 74%, 70% and 51%. Neutral survival time was 48 months, and the progression-free time of neutral position was 15 months. Multi-factor analysis indicated that,ECOG<2 and ECOG≥2(P=0000),BED10<100 Gy and BED10≥100 Gy ( P=0006) generated obvious influence on survival prognosis. About 90% of the patients only got 1-2 degree of adverse reaction without emerging treatment related death. Conclusions On the premise of systematic therapy of oligometastasis non-small cell lung cancer, combined with radical radiotherapy of primary lesion and metastasis can obviously improve patients ' overall survival and progression-free survival,the adverse reaction is durable.
